MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter -derived cephalosporinases ( ADCs ) β-lactamase variants with K i values <1 μM. MB076 acts synergistically in combination with multiple cephalosporins to restore pBCSK(-) susceptibility.
Products | Products > Disease Areas > Infection | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > Bacterial
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.